Company logo

TNXP - Tonix Pharmaceuticals Holding Corp.

NASDAQ -> Healthcare -> Biotechnology
Chatham, United States
Type: Equity

TNXP price evolution
TNXP
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Current assets
Cash $4.16 $7.05 $24.95
Short term investments
Net receivables $6.67 $3.34
Inventory $8.27 $9.46 $12.35 $13.64
Total current assets $50.54 $25.29 $30.1 $47.77
Long term investments
Property, plant & equipment $43.38 $43.94 $93.81 $94.85
Goodwill & intangible assets $0.12 $10.47 $10.71
Total noncurrent assets $45.02 $105.25 $106.69
Total investments
Total assets $94.99 $70.31 $135.34 $154.46
Current liabilities
Accounts payable $3.94 $10.41 $6.65 $3.78
Deferred revenue
Short long term debt $3.1 $3.1 $2.62
Total current liabilities $15.18 $22.04 $20.48 $18.88
Long term debt $5.17 $6.16 $6.72 $7.19
Total noncurrent liabilities $6.16 $6.72 $30.05
Total debt $9.26 $9.82 $9.81
Total liabilities $20.78 $28.2 $27.2 $48.93
Shareholders' equity
Retained earnings -$708.59 -$694.37 -$615.6 -$600.66
Other shareholder equity -$0.25 -$0.24 -$0.24 -$0.23
Total shareholder equity $42.1 $108.14 $105.53
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $24.95 $120.23 $178.9 $77.31
Short term investments
Net receivables
Inventory $13.64
Total current assets $47.77 $130.78 $189.05 $87.99
Long term investments
Property, plant & equipment $94.85 $94.53 $51.47 $9.83
Goodwill & intangible assets $10.71 $0.12 $0.12
Total noncurrent assets $106.69 $94.91 $51.85 $10.19
Total investments
Total assets $154.46 $225.69 $240.9 $98.18
Current liabilities
Accounts payable $3.78 $8.07 $13.28 $4.6
Deferred revenue
Short long term debt $2.62 $0.43 $0.49 $0.59
Total current liabilities $18.88 $18.18 $21.72 $9.82
Long term debt $7.19 $0.33 $0.47 $0.72
Total noncurrent liabilities $30.05 $0.33 $0.47 $0.72
Total debt $9.81 $0.76 $0.96 $1.31
Total liabilities $48.93 $18.51 $22.18 $10.54
Shareholders' equity
Retained earnings -$600.66 -$470.04 -$359.82 -$267.53
Other shareholder equity -$0.23 -$0.17 -$0.09 -$0.06
Total shareholder equity $105.53 $207.18 $218.72 $87.65
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Revenue
Total revenue $2.82 $2.21 $2.48 $3.78
Cost of revenue $3.37 $1.66 $2.37
Gross Profit $1.27 -$1.16 $0.82 $1.41
Operating activities
Research & development $9.7 $12.86 $17.12
Selling, general & administrative $7.5 $9.31 $11.62
Total operating expenses $16.82 $76.16 $22.17 $28.74
Operating income -$77.32 -$21.35 -$27.33
Income from continuing operations
EBIT -$78.78 -$14.94 -$27.32
Income tax expense
Interest expense
Net income
Net income -$14.21 -$78.78 -$14.94 -$27.32
Income (for common shares) -$78.78 -$14.94 -$27.32
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $7.77
Cost of revenue $4.74
Gross Profit $3.03
Operating activities
Research & development $86.66 $81.88 $68.84 $36.16
Selling, general & administrative $34.75 $30.21 $23.47 $14.35
Total operating expenses $121.41 $112.09 $92.31 $50.51
Operating income -$118.38 -$112.09 -$92.31 -$50.51
Income from continuing operations
EBIT -$116.66 -$110.22 -$92.29 -$50.46
Income tax expense
Interest expense
Net income
Net income -$116.66 -$110.22 -$92.29 -$50.46
Income (for common shares) -$116.66 -$116.88 -$92.29 -$52.17
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income -$78.78 -$14.94 -$27.32
Operating activities
Depreciation $1.21 $1.21 $1.26
Business acquisitions & disposals
Stock-based compensation $1.15 $1.69 $2.04
Total cash flows from operations -$9.92 -$17.57 -$22.34
Investing activities
Capital expenditures -$0.11 -$0.43
Investments
Total cash flows from investing -$0.12 -$0.11 -$0.43
Financing activities
Dividends paid
Sale and purchase of stock $10.73 $0.02 $9.2
Net borrowings -$0.7 -$0.23 $8.94
Total cash flows from financing $49.72 $7.03 -$0.21 $40.71
Effect of exchange rate -$0.02 $0 -$0 -$0.01
Change in cash and equivalents $3.29 -$2.89 -$17.9 $17.93
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$116.66 -$110.22 -$92.29 -$50.46
Operating activities
Depreciation $4.29 $1.25 $0.05 $0.03
Business acquisitions & disposals -$22.17
Stock-based compensation $9.28 $10.91 $7.9 $2.88
Total cash flows from operations -$102 -$98.05 -$75.56 -$48.57
Investing activities
Capital expenditures -$6.9 -$48.15 -$35.31 -$8.56
Investments
Total cash flows from investing -$29.07 -$48.15 -$35.31 -$8.56
Financing activities
Dividends paid $4.6
Sale and purchase of stock $5 $94.5 $212.49 $118.5
Net borrowings $8.94
Total cash flows from financing $36.52 $87.84 $212.49 $123.11
Effect of exchange rate -$0.07 -$0.07 -$0.03 -$0.02
Change in cash and equivalents -$94.62 -$58.43 $101.59 $65.96
Fundamentals
Market cap $59.14M
Enterprise value N/A
Shares outstanding 155.63M
Revenue $11.29M
EBITDA N/A
EBIT N/A
Net Income -$135.25M
Revenue Q/Q -29.26%
Revenue Y/Y 183.05%
P/E ratio -0.44
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 5.24
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.87
ROA -118.88%
ROE N/A
Debt/Equity 0.46
Net debt/EBITDA N/A
Current ratio 3.33
Quick ratio 2.78